Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Persistent Opioid Use After Hysterectomy

Am J Obstet Gynecol; ePub 2018 Jun 18; Swenson, et al

The prevalence of new persistent opioid use among opioid naïve women undergoing hysterectomy is low; however, 2 potentially modifiable factors are preoperative opioid prescription and abdominal route of surgery. This according to a study that sought to determine a data-driven definition of new persistent opioid use among this population, and to determine the prevalence of and risk factors for new persistent opioid use. Researchers identified hysterectomies performed from January 1, 2011 to December 31, 2014. Inclusion criteria included: age ≤63 years at hysterectomy, no opioid fills for 8 months preceding, and no additional surgical procedures within 6 months post-hysterectomy. They found:

  • 24,331 women were included in the analysis.
  • “New persistent opioid use” was defined as: ≥2 opioid fills within 6 months of hysterectomy with ≥1 fill every 3 months, and either total oral morphine equivalent ≥1,150 or day’s supplied ≥39.
  • Based on this definition, the prevalence of new persistent opioid use was 0.5%.
  • Factors independently associated with new persistent opioid use included: increasing age, black race, gynecologic malignancy, abdominal route, depression/anxiety, and preoperative opioid fill.

Citation:

Swenson CW, Kamdar NS, Seiler K, Morgan DM, Lin P, As-Sanie S. Definition development and prevalence of new persistent opioid use following hysterectomy. [Published online ahead of print June 18, 2018]. Am J Obstet Gynecol. doi:10.1016/j.ajog.2018.06.010.